These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30227753)

  • 1. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma.
    Matsou A; Anastasopoulos E
    Expert Opin Investig Drugs; 2018 Oct; 27(10):777-785. PubMed ID: 30227753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018).
    Angeli A; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):793-803. PubMed ID: 31462124
    [No Abstract]   [Full Text] [Related]  

  • 3. Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors.
    Lusthaus JA; Goldberg I
    Expert Opin Emerg Drugs; 2016; 21(1):117-28. PubMed ID: 26854598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review.
    Moshegov S; Kerr NM
    Expert Opin Investig Drugs; 2023; 32(11):1017-1023. PubMed ID: 37929314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
    Sharif NA; Odani-Kawabata N; Lu F; Pinchuk L
    Exp Eye Res; 2023 Apr; 229():109415. PubMed ID: 36803996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.
    Impagnatiello F; Bastia E; Almirante N; Brambilla S; Duquesroix B; Kothe AC; Bergamini MVW
    Br J Pharmacol; 2019 Apr; 176(8):1079-1089. PubMed ID: 29669171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.
    Lusthaus JA; Goldberg I
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1201-8. PubMed ID: 27548834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
    Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapy for glaucoma: what to add after a prostaglandin analogs?
    Tanna AP; Lin AB
    Curr Opin Ophthalmol; 2015 Mar; 26(2):116-20. PubMed ID: 25594765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandins in the eye: Function, expression, and roles in glaucoma.
    Doucette LP; Walter MA
    Ophthalmic Genet; 2017; 38(2):108-116. PubMed ID: 27070211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between topical prostaglandin analog use and development of choroidal neovascular membranes in patients with concurrent glaucoma and age-related macular degeneration.
    Scherer WJ
    J Ocul Pharmacol Ther; 2006 Apr; 22(2):139-44. PubMed ID: 16722800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells.
    Kalouche G; Beguier F; Bakria M; Melik-Parsadaniantz S; Leriche C; Debeir T; Rostène W; Baudouin C; Vigé X
    Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1816-25. PubMed ID: 27082296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension.
    Katsanos A; Riva I; Bozkurt B; Holló G; Quaranta L; Oddone F; Irkec M; Dutton GN; Konstas AG
    Expert Opin Drug Saf; 2022 Apr; 21(4):525-539. PubMed ID: 34666576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
    Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
    Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study.
    Iskedjian M; Walker JH; Desjardins O; Robin AL; Covert DW; Bergamini MV; Einarson TR
    Curr Med Res Opin; 2009 Aug; 25(8):1879-88. PubMed ID: 19530975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New classes of glaucoma medications.
    Schehlein EM; Novack GD; Robin AL
    Curr Opin Ophthalmol; 2017 Mar; 28(2):161-168. PubMed ID: 27828896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.
    Holló G; Katsanos A; Boboridis KG; Irkec M; Konstas AGP
    Drugs; 2018 Jan; 78(1):39-64. PubMed ID: 29196953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
    Matsuo M; Matsuoka Y; Tanito M
    Clin Ophthalmol; 2022; 16():1261-1279. PubMed ID: 35510270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of prostaglandin analogues on aqueous humor outflow pathways.
    Winkler NS; Fautsch MP
    J Ocul Pharmacol Ther; 2014; 30(2-3):102-9. PubMed ID: 24359106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of glaucoma: focus on pharmacological therapy.
    Marquis RE; Whitson JT
    Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.